Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea

• Main Authors: Min Hyuk Choi, Hyunmin Ahn, Han Seok Ryu, Byung-Jun Kim, Joonyong Jang, Moonki Jung, Jinuoung Kim, Seok Hoon Jeong
• Format: Article
• Language: English
• Published: MDPI AG 2020-06-01
• Series: Journal of Clinical Medicine
• Subjects: coronavirus disease-19 (COVID-19); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); angiotensin II receptor blockers (ARB); ibuprofen; Korea centers for disease control and prevention (KCDC) classification
• Online Access: https://www.mdpi.com/2077-0383/9/6/1959

A rapid increase in the number of patients with coronavirus disease 19 (COVID-19) may overwhelm the available medical resources. We aimed to evaluate risk factors for disease severity in the early stages of COVID-19. The cohort comprised 293 patients with COVID-19 from 5 March 2020, to 18 March 2020. The Korea Centers for Disease Control and Prevention (KCDC) classification system was used to triage patients. The clinical course was summarized, including the impact of drugs (angiotensin II receptor blockers [ARB], ibuprofen, and dipeptidyl peptidase-4 inhibitors [DPP4i]) and the therapeutic effect of lopinavir/ritonavir. After adjusting for confounding variables, prior history of drug use, including ARB, ibuprofen, and DPP4i was not a risk factor associated with disease progression. Patients treated with lopinavir/ritonavir had significantly shorter progression-free survival than those not receiving lopinavir/ritonavir. KCDC classification I clearly distinguished the improvement/stabilization group from the progression group of COVID-19 patients (AUC 0.817; 95% CI, 0.740–0.895).